These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 11845256

  • 1. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
    Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, Bebbington C, Yarranton G.
    Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
    [Abstract] [Full Text] [Related]

  • 2. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.
    Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, Tedesco F, Rambaldi A, Introna M.
    Blood; 2000 Jun 15; 95(12):3900-8. PubMed ID: 10845926
    [Abstract] [Full Text] [Related]

  • 3. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.
    Shan D, Ledbetter JA, Press OW.
    Cancer Immunol Immunother; 2000 Mar 15; 48(12):673-83. PubMed ID: 10752475
    [Abstract] [Full Text] [Related]

  • 4. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.
    Harjunpää A, Junnikkala S, Meri S.
    Scand J Immunol; 2000 Jun 15; 51(6):634-41. PubMed ID: 10849376
    [Abstract] [Full Text] [Related]

  • 5. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E.
    Haematologica; 2002 Jan 15; 87(1):33-43. PubMed ID: 11801463
    [Abstract] [Full Text] [Related]

  • 6. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
    Brezski RJ, Kinder M, Grugan KD, Soring KL, Carton J, Greenplate AR, Petley T, Capaldi D, Brosnan K, Emmell E, Watson S, Jordan RE.
    MAbs; 2014 Jan 15; 6(5):1265-73. PubMed ID: 25517311
    [Abstract] [Full Text] [Related]

  • 7. Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.
    Engelberts PJ, Voorhorst M, Schuurman J, van Meerten T, Bakker JM, Vink T, Mackus WJ, Breij EC, Derer S, Valerius T, van de Winkel JG, Parren PW, Beurskens FJ.
    J Immunol; 2016 Dec 15; 197(12):4829-4837. PubMed ID: 27807190
    [Abstract] [Full Text] [Related]

  • 8. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.
    Stein R, Qu Z, Chen S, Solis D, Hansen HJ, Goldenberg DM.
    Blood; 2006 Oct 15; 108(8):2736-44. PubMed ID: 16778139
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of human B-cell lymphoma by an anti-CD20 antibody and its chimeric F(ab')2 fragment via induction of apoptosis.
    Liu Y, Zheng M, Lai Z, Xiong D, Fan D, Xu Y, Peng H, Shao X, Xu Y, Yang M, Wang J, Liu H, Xie Y, Yang C, Zhu Z.
    Cancer Lett; 2004 Mar 18; 205(2):143-53. PubMed ID: 15036646
    [Abstract] [Full Text] [Related]

  • 10. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
    Weng WK, Levy R.
    Blood; 2001 Sep 01; 98(5):1352-7. PubMed ID: 11520782
    [Abstract] [Full Text] [Related]

  • 11. Expression and biological characterization of an anti-CD20 biosimilar candidate antibody: a case study.
    Dorvignit D, Palacios JL, Merino M, Hernández T, Sosa K, Casaco A, López-Requena A, Mateo de Acosta C.
    MAbs; 2012 Sep 01; 4(4):488-96. PubMed ID: 22647435
    [Abstract] [Full Text] [Related]

  • 12. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils.
    van der Kolk LE, de Haas M, Grillo-López AJ, Baars JW, van Oers MH.
    Leukemia; 2002 Apr 01; 16(4):693-9. PubMed ID: 11960351
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
    Bornstein GG, Quéva C, Tabrizi M, van Abbema A, Chavez C, Wang P, Foord O, Ahluwalia K, Laing N, Raja S, Wen S, Green LL, Yang X, Webster C, Stewart R, Blakey D.
    Invest New Drugs; 2010 Oct 01; 28(5):561-74. PubMed ID: 19626278
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
    Flavell DJ, Warnes SL, Bryson CJ, Field SA, Noss AL, Packham G, Flavell SU.
    Br J Haematol; 2006 Jul 01; 134(2):157-70. PubMed ID: 16771848
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity.
    Natsume A, Shimizu-Yokoyama Y, Satoh M, Shitara K, Niwa R.
    Cancer Sci; 2009 Dec 01; 100(12):2411-8. PubMed ID: 19758394
    [Abstract] [Full Text] [Related]

  • 20. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
    Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC.
    J Immunother; 2001 Dec 01; 24(3):263-71. PubMed ID: 11394505
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.